Drugs / AXA-NK02
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT07412210 | Apr 2026 → Mar 2029 expected | lupus nephritis | Shanghai Jiao Tong University School of Medicine | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AXA-NK02 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07412210 ↗ |
| Modality | Cell therapy | “Off-the-shelf NK cell products derived from human embryonic stem cells (hESCs)” NCT07412210 ↗ |